- Bristol-Myers Squibb sells off diabetes business
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- 'Road to Healthy Skin' tour wraps up sixth year of free skin cancer screenings
- Generics to drive down HIV drug sales in next decade
PRINCETON, N.J. — A cancer drug made by Bristol-Myers Squibb has received an award from Galien Foundation, the drug maker said Wednesday.
The company said Yervoy (ipilimumab) received the 2012 Prix Galien USA Prize in the Best Biotechnology Product category. Yervoy — used to treat melanoma that has spread to other parts of the body, known as metastasis — is the first new drug for melanoma that is metastatic or can't be removed through surgery in more than a decade.
The selection committee for the ceremony includes several Nobel Laureates, and the drug has been shortlisted for the Prix Galien Prize in Germany, Bristol-Myers Squibb said.